Oberland Capital Invests up to $600 Million in Biohaven

San Francisco – April 28, 2025 – Cooley advised Oberland Capital Management, a private investment firm committed to funding innovation across the global healthcare industry, on its agreement to invest up to $600 million in Biohaven (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Under the note purchase agreement, Oberland Capital may purchase up to $600 million of Biohaven’s senior secured notes, of which $250 million will be funded on or before April 30, 2025, $150 million will be funded at Biohaven’s option, contingent upon the US Food and Drug Administration’s approval of troriluzole and subject to the satisfaction of certain additional conditions, and $200 million will be funded upon the mutual agreement of the parties for permitted strategic acquisitions and related costs.

Cooley partner Mischi a Marca led the Cooley team advising Oberland Capital.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.